• Nasodine Nasal Spray approved in Indonesia, the largest market in Southeast Asia
• Nasodine® Throat Spray launched into Singapore and Fiji
• Key international appointments to expand global growth potential

Firebrick Pharma Ltd (ASX:FRE) has provided its business activity update for the quarter ending 31 March 2026, along with its Appendix 4C quarterly cash flow report. Key highlights include the approval of Nasodine Nasal Spray in Indonesia, the largest market in Southeast Asia, and the launch of Nasodine® Throat Spray in Singapore and Fiji. The company also announced the appointments of Al Moghaddam as a Non-Executive Director and Nilesh Wadhwa as Head of Business Development and Licensing, both of whom bring extensive experience in the global pharmaceutical industry. Firebrick's goal is to grow from 2 products in 3 countries to 4 products in up to 10 countries over the next three years, and these appointments are expected to be key in achieving that goal. Financially, the company reported a 26% increase in base operating expenses in the March quarter due to one-off costs related to regulatory, business development, and recruitment activities. However, expenses are expected to return to levels similar to the December quarter in the upcoming period. The company also secured $1.5 million in new funding through a private placement, ensuring a 12-month runway for future operations.

The company's goal is to grow from 2 products in 3 countries to 4 products in up to 10 countries over the next three years, supported by the recent key executive appointments.